Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02826603 · ClinicalTrials.gov registry record · Phase 3
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,114
- Enrollment target
NCT02826603 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,114 participants.
The verdict
NCT02826603, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,114 participants
- Enrollment target
Study Summary
Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
Interventions
- DRUG Ustekinumab
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,114 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2018-07-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02826603
The ClinicalTrials.gov registry entry for NCT02826603 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ustekinumab is the first listed.
NCT02826603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02826603 about?
NCT02826603 is a clinical study titled "Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis". Demonstrate superiority of secukinumab over ustekinumab in treatment of moderate to severe plaque psoriasis.
What is the current status of trial NCT02826603?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,114 participants. The study started on 2016-06-22. Estimated completion is 2018-07-09.
What interventions are being tested in trial NCT02826603?
The interventions under investigation include: Ustekinumab (DRUG), Secukinumab (DRUG).
Who is sponsoring clinical trial NCT02826603?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.